Onto Innovation, OSI Systems, NVE, Nano Dimension, Clene, Biodexa Pharmaceuticals, and Virpax Pharmaceuticals are the seven Nanotechnology stocks to watch today, according to MarketBeat's stock screener tool. Nanotechnology stocks are equity shares of companies that research, develop or commercialize products and processes at the nanoscale (typically 1–100 nanometers). By investing in these stocks, shareholders gain exposure to emerging applications in electronics, medicine, energy and materials science. Because nanotech ventures often involve high R&D costs and long development timelines, these equities can exhibit significant volatility. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.
Onto Innovation (ONTO)
Onto Innovation Inc. engages in the design, development, manufacture, and support of process control tools that performs optical metrology. The company offers lithography systems and process control analytical software. It also offers process and yield management solutions, and device packaging and test facilities through standalone systems for optical metrology, macro-defect inspection, packaging lithography, and transparent and opaque thin film measurements.
ONTO traded down $4.96 during trading on Monday, hitting $99.08. The company had a trading volume of 497,093 shares, compared to its average volume of 1,243,549. Onto Innovation has a 1-year low of $85.88 and a 1-year high of $238.93. The business has a 50-day moving average of $101.89 and a 200-day moving average of $138.37. The company has a market cap of $4.84 billion, a PE ratio of 22.42, a P/E/G ratio of 0.68 and a beta of 1.45.
Read Our Latest Research Report on ONTO
OSI Systems (OSIS)
OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.
OSIS stock traded down $2.72 during trading on Monday, hitting $229.79. 95,389 shares of the company's stock traded hands, compared to its average volume of 232,688. The company has a quick ratio of 1.38, a current ratio of 2.11 and a debt-to-equity ratio of 0.53. OSI Systems has a 52 week low of $129.18 and a 52 week high of $241.64. The stock has a fifty day moving average price of $223.08 and a two-hundred day moving average price of $200.29. The stock has a market capitalization of $3.86 billion, a price-to-earnings ratio of 27.95, a price-to-earnings-growth ratio of 1.97 and a beta of 1.27.
Read Our Latest Research Report on OSIS
NVE (NVEC)
NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.
NVEC stock traded down $1.74 during trading on Monday, hitting $74.76. 59,052 shares of the company's stock traded hands, compared to its average volume of 38,907. NVE has a 52 week low of $51.50 and a 52 week high of $89.98. The stock has a fifty day moving average price of $70.01 and a two-hundred day moving average price of $69.94. The stock has a market capitalization of $361.61 million, a price-to-earnings ratio of 24.04 and a beta of 1.15.
Read Our Latest Research Report on NVEC
Nano Dimension (NNDM)
Nano Dimension Ltd., together with its subsidiaries, engages in additive manufacturing solutions in Israel and internationally. The company offers 3D printers, comprising AME systems, which are inkjet printers, that produces Hi-PEDs by depositing proprietary conductive and dielectric substances, as well as integrates in-situ capacitors, antennas, coils, transformers, and electromechanical components; micro additive manufacturing systems, a digital light processing printers (DLP) that achieves production-grade polymer and composite parts; and industrial additive manufacturing systems, that utilizes a patented foil system that fabricates ceramic and metal parts.
NNDM stock traded down $0.06 during trading on Monday, hitting $1.56. 1,100,403 shares of the company's stock traded hands, compared to its average volume of 1,649,728. Nano Dimension has a 52 week low of $1.34 and a 52 week high of $2.74. The stock has a fifty day moving average price of $1.55 and a two-hundred day moving average price of $1.92. The stock has a market capitalization of $337.87 million, a price-to-earnings ratio of -3.89 and a beta of 1.13.
Read Our Latest Research Report on NNDM
Clene (CLNN)
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
CLNN stock traded up $0.01 during trading on Monday, hitting $3.91. 33,859 shares of the company's stock traded hands, compared to its average volume of 90,687. Clene has a 52 week low of $2.28 and a 52 week high of $7.00. The stock has a fifty day moving average price of $3.43 and a two-hundred day moving average price of $3.95. The stock has a market capitalization of $35.12 million, a price-to-earnings ratio of -0.97 and a beta of 0.55.
Read Our Latest Research Report on CLNN
Biodexa Pharmaceuticals (BDRX)
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Shares of Biodexa Pharmaceuticals stock traded up $0.01 during trading on Monday, hitting $0.87. 122,056 shares of the stock were exchanged, compared to its average volume of 1,098,601. The stock's fifty day moving average is $1.15 and its 200 day moving average is $2.44. The company has a quick ratio of 1.75, a current ratio of 1.75 and a debt-to-equity ratio of 0.01. Biodexa Pharmaceuticals has a 12 month low of $0.78 and a 12 month high of $41.50.
Read Our Latest Research Report on BDRX
Virpax Pharmaceuticals (VRPX)
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.
Shares of Virpax Pharmaceuticals stock traded up $0.00 during trading on Monday, hitting $0.39. 19,498 shares of the stock were exchanged, compared to its average volume of 206,165. The stock's fifty day moving average is $0.27 and its 200 day moving average is $3.47. Virpax Pharmaceuticals has a 12 month low of $0.13 and a 12 month high of $84.75.
Read Our Latest Research Report on VRPX
Featured Articles
Before you consider Onto Innovation, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Onto Innovation wasn't on the list.
While Onto Innovation currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
